Press Releases March 26, 2026 08:33 AM

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report

Golar LNG Limited Files Form 20-F Annual Report for 2025

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
GLNG

Golar LNG Limited has filed its Form 20-F annual report for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission, making the report available for shareholders and public access.

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report
GLNG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Form 20-F for 2025 was filed with the SEC as required for foreign private issuers listed in the U.S.
  • The report is accessible on Golar LNG's website and shareholders can request a hard copy free of charge.
  • The disclosure complies with Norwegian Securities Trading Act requirements.

Golar LNG Limited announces that it has filed its Form 20-F for the year ended December 31, 2025, with the Securities and Exchange Commission in the U.S.

Form 20-F can be downloaded from the link below, is available on our website www.golarlng.com and shareholders may receive a hard copy free of charge upon request. 

March 26, 2026
The Board of Directors
Hamilton, Bermuda

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


Risks

  • Market reaction to annual reports can vary based on financial performance details within the filing, which are not detailed here.
  • The LNG sector is exposed to fluctuating global energy prices and regulatory changes affecting demand and supply.
  • Geopolitical risks and shipping industry factors could impact Golar LNG's business prospects.

More from Press Releases

Robinhood Ventures Fund II (RVII) Announces Pricing of Initial Public Offering Aug 13, 2026 Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older Aug 13, 2026 Duolingo Invests in World-Class Motion Design with Acquisition of Animade Aug 13, 2026 Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Aug 12, 2026 Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Aug 12, 2026